Table 1.
Demographics
| Characteristic | Value |
| N | 10 |
| Age in years, mean±SD | 43.3±8.4 |
| Male sex, n (%) | 6 (60) |
| Black race, n (%) | 7 (70) |
| Cause of ESKD, n (%) | |
| Hypertension | 3 (30) |
| Polycystic kidney disease | 3 (30) |
| Autoimmune kidney disease | 4 (40) |
| Average time of dialysis, yr±SD | 4.16±4.32 |
| Retransplant, n (%) | 4 (40) |
| Percentage cPRA, mean±SD | 42±42 |
| Delayed graft function, n (%) | 4 (40) |
| Positive donor-specific antibody at transplant, n (%) | 2 (20) |
| Positive donor-specific antibody at TCZ, n (%) | 8 (80) |
| Acute rejection before TCZ, n (%) | 8 (80) |
| Time to TCZ in months, mean±SD | 40±31 |
| Pre-TCZ eGFR in ml/min per 1.73 m2, mean±SD | 42±19 |
| Pre-TCZ proteinuria in g/g, mean±SD | 1.5±1.14 |
| Pre-TCZ microvascular inflammation (g+ptc), mean±SD | 4.1±1.5 |
| Pre-TCZ AbMR score (MMDx), mean±SD | 0.76±0.23 |
| Pre-TCZ TCMR score (MMDx), mean±SD | 0.04±0.09 |
| Donor characteristics | |
| Donor age in years, mean±SD | 43±13 |
| Living donor kidney transplant, n (%) | 6 (60) |
| Median kidney donor profile index, % (range)a | 44 (25–97) |
| Immunosuppression | |
| Mycophenolate+prednisone+belatacept, n (%) | 7 (70) |
| Mycophenolate+prednisone+tacrolimus, n (%) | 3 (30) |
| Mean mycophenolate dose at TCZ, g/d±SD | 1.78±0.34 |
| Median follow-up after TCZ, mo (range) | 12 (8–24) |
| Median TCZ doses, n (range) | 6 (3–10) |
cPRA, calculated panel-reactive antibody; TCZ, tocilizumab; g+ptc, glomerulitis and peritubular capillaritis score; AbMR, antibody-mediated rejection; MMDx, Molecular Microscope Diagnostic System; TCMR, T cell–mediated rejection.
a
Kidney Donor Profile Index calculated for deceased donor kidney transplants only.